Literature DB >> 14962434

Four cases of normal-tension glaucoma with disk hemorrhage combined with branch retinal vein occlusion in the contralateral eye.

Sang Jin Kim1, Ki Ho Park.   

Abstract

PURPOSE: To report four cases of normal-tension glaucoma with disk hemorrhage in one eye and branch retinal vein occlusion in the contralateral eye.
DESIGN: Observational case series.
METHODS: Four cases of normal-tension glaucoma with disk hemorrhage in one eye and branch retinal vein occlusion in the contralateral eye were detected within a 1-year period.
RESULTS: Mean patient age was 57 +/- 10 years. Three patients had systemic hypertension, two bilateral normal-tension glaucoma, and all four bilateral peripapillary atrophy. There was no significant difference in intraocular pressure between the disk hemorrhage eyes and the contralateral eyes with branch retinal vein occlusion.
CONCLUSION: Some normal-tension glaucoma patients with disk hemorrhage may have a pathogenic mechanism in combination with branch retinal vein occlusion.

Entities:  

Mesh:

Year:  2004        PMID: 14962434     DOI: 10.1016/S0002-9394(03)00875-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

1.  Altered temporal peripapillary retinal flow in patients with disc hemorrhages.

Authors:  Leena Kurvinen; Mika Harju; Jukka Saari; Eija Vesti
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-07-16       Impact factor: 3.117

2.  Disc hemorrhages in patients with both normal tension glaucoma and branch retinal vein occlusion in different eyes.

Authors:  Young Cheol Yoo; Ki Ho Park
Journal:  Korean J Ophthalmol       Date:  2007-12

3.  Evaluation of the relationship between glaucomatous disc subtypes and occurrence of disc hemorrhage and glaucoma progression in open angle glaucoma.

Authors:  Akiko Yamagami; Astuo Tomidokoro; Shun Matsumoto; Yoshio Yamazaki; Keiji Yoshikawa; Junkichi Yamagami; Goji Tomita; Makoto Araie
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.